Giant Biogene Holding (2367) Fair Value & Analysis
Consumer Defensive · HK · Market cap HK$28.3B
Fair value as of: Aug 5, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Aug 5, 2026, revised from HK$37.04 to HK$37.24 (+0.5%) since Jul 2, 2026. Share price +9.4% over the past month.
A solid business, screening 31% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$29.41). The market is more pessimistic than our downside scenario.
- Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.
How to read this chart
45‑month range HK$22.65 – HK$79.15 · fair‑value band HK$29.41 – HK$46.62 · the HK$28.42 price screens below the HK$37.24 fair value. Dashed = 300-day average. As of Aug 5, 2026.
Analysis
Giant Biogene Holding (2367) currently trades at HK$28.42, while our model-based Fair Value estimate is HK$37.24, implying the stock looks roughly 31.0% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Giant Biogene Holding generated revenue of HK$5.5B at a net margin of 34.7%. Revenue declined 19.8% year over year. It earns a return on equity of 22.5%. The balance sheet holds a net cash position of HK$6.3B. Fundamentals as of Aug 5, 2026
Our scenario range runs from HK$29.41 (bear case) to HK$46.62 (bull case); at HK$28.42, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 55% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at 31%, 2367 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$82.57) versus Asset-Based (HK$6.26). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China.
Full company description
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Giant Biogene Holding reported revenue of HK$5.5B in FY2025 versus HK$1.6B in FY2021, a compound +37.3%/yr. Reported net income was HK$1.9B in FY2025, compounding +23.3%/yr from FY2021.
Watch 2367: get an alert when its fair value changes →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Giant Biogene Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Giant Biogene Holding (2367) overvalued or undervalued?
What is the fair value of 2367?
What is the quality score of 2367?
What is the revenue of Giant Biogene Holding (2367)?
What is the net profit margin of 2367?
Does Giant Biogene Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Giant Biogene Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.